8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – June 6, 2011

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Item 7.01.  Regulation FD Disclosure.

On June 6, 2011, our management will present at the Jefferies 2011 Healthcare Conference in New York, New York at 4:00 PM ET.  A copy of the presentation materials from the conference will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01.  Financial Statements and Exhibits.

(d)	Exhibits
	Exhibit 99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III, Vice President, General

Counsel and Secretary

June 6, 2011

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

4

EX-99.1

WEST PHARMACEUTICAL SERVICES OVERVIEW

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

Jefferies2011 Global Healthcare Conference

New York, NY

June 6, 2011

Safe Harbor Statement

2

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995

This presentation and any accompanying management commentary contain “forward-looking statements”
as that term is defined in the Private Securities Litigation Reform Act of 1995.Such statements include,
but are not limited to statements about expected financial results for 2011 and future years.

Each of these estimates is based on preliminary information, and actual results could differ from these
preliminary estimates.We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.

Non-GAAP Financial Measures

Certain financial measures included in these presentation materials, and which may be referred to in
management’s discussion of the Company’s results and outlook, are Non-GAAP (Generally Accepted
Accounting Principles) financial measures. Please refer to the “Non-GAAP Financial Measures” and
“Notes to Non-GAAP Financial Measures” at the end of these materials for more information.Non-GAAP
financial measures should not be considered in isolation or as an alternative to such measures
determined in accordance with GAAP.

West is a globally diversified manufacturer of products consumed in the healthcare
and consumer markets.

On average, approximately 100 million components manufactured by West and
our partner Daikyo are used to enhance the quality of healthcare worldwide
everyday.

3

A Diverse, Stable Customer Base

Pharmaceutical/Biotech

Generic

Medical Device

4

Sales($ in millions)

5

Compound annual growth rate: 8.9%

2011 Market Outlook

•Uncertain and asymmetric global economic recovery

–Europe, US, Japan remain sluggish

–China, India, Brazil stronger

–Continuing Fx, commodity price volatility

•More demanding regulatory environment

–Increased scrutiny of pharmaceutical operations

•Broader trends in Pharma/Device markets continue:

–Unknown impact of healthcare legislation

–Thin near term pipelines

–Pharma M&A - shift to large molecules

–Increased manufacturing outsourcing (India generic growth)

6

2010 Segment Reorganization

Packaging Systems

•Established leadership

•High market share

•Stable growth rate

Delivery Systems

•Proprietary devices

•Contract manufacturing

•High projected growth rate

Development

Primary Package

Administration

7

$785M

$324M

•Pharmaceutical Packaging Segment

–Demographics and increasing prevalence of chronic disease

–Biologics

–Growth in Emerging Markets

–Increased access to Healthcare

–Escalating quality expectations: “Zero Defects”

•Delivery Systems Segment

–Demand for combination products that promote safety, dosing accuracy,
ease of use, and deliver cost savings

–Drug product life cycle management

–Glass compatibility/breakage issues

What will Drive Future Growth?

8

Category	Key Customers	Projected Growth
Diabetes		> 10 %
Oncology		> 10 %
Vaccines		> 10 %
Autoimmune		>8%
Generics		>10%

IMS April 2010 Report; Business Insights 2009; GBI Research 2009

9

Therapeutic Category Growth Drivers

Pharmaceutical Packaging SystemsPackaging Components for Small Volume Parenterals

Plungers, Tip caps, Needle
shields for Glass Syringes

Plungers, lined seals for
Glass Cartridges for Pens

Closures for Glass
Vials

10

Packaging Systems Segment

•Increase per-unit value

•Improve operating efficiency: lean operations

•Geographic expansion - capacity investments in Asia

•Strategic acquisitions and partnerships

Growth Strategy

11

12

Packaging Opportunity

Gross Margin
Opportunity

Revenue Opportunity ($ per 1,000 units)

Plungers and
sleeve stoppers

Stoppers

Seals

RU seals

Westar® RS

Faster Growth of High-Value ProductsPharmaceutical Packaging Systems

13

Delivery Systems

West ConfiDose®
Auto-injector System

Daikyo Crystal Zenith
Life-cycle Containment Solutions

West Electronic
Patch injector

14

West MixJect® and
Vial2Bag®

Custom Manufacturing of
Components and Devices

Proprietary Components, Devices and Systems

Delivery Systems Segment

•Leverage life-cycle management opportunities

•Realize commercial potential of CZ

•Develop new platform opportunities - combination products

•Custom solution provider

Growth Strategy

15

16

PDS Opportunity

Gross Margin
Opportunity

Revenue Opportunity ($/1,000 units)

Consumer products

Consumer
device
manufacturing

Mix2Vial®

CZ vials

CZ Syringes

ConfiDose®

Electronic patch
injector

Pharma Industry Drug Life-Cycle
Management

Phase I

Phase II

Phase III

Post-Market Life Cycle Management

8 - 10 years

2 - 3 years

2 - 3 years

Regulatory

Approval

Discovery

17

Concerns With Glass Syringes

•Interaction with sensitive biologics

•Protein aggregation (silicone oil)

•Residual chemicals (tungsten, glue)

•Glass flakes

•Breakage

•In process

•Within auto-injector systems

•Recent FDA recalls

•Dimensional variation

•Breakage in auto-injector systems

•Designed for manual injection

•Variable silicone distribution

•Amount of silicone coverage

•Age of barrel

•Inconsistent break force and
sustaining-force

•Quality

•Cosmetic defects

•High levels of inspection necessary

•High “cost of quality”

Siliconized Glass Syringe

Crystal Zenith Syringe

18

2010 Glass-related Recalls

19

Electronic Patch Injector

Programmed by PDA or PC

Dose may be customized

Applied and activated by patient

20

•Controlled, subcutaneous, micro-infusion delivery
of high volumes and high viscosity drugs

•Prefilled cartridge, no need for user filling

•Based on Daikyo CZ cartridge

•Compact

•Hidden needle for safety

•Single push-button operation

Prototype Operation

Custom Delivery Device Utilizing
Daikyo Crystal Zenith

21

Our Long-Term Focus

•Pharmaceutical Packaging Systems

–Organic growth (on average) of 3-5% per year

–Margin expansion through operating efficiency, product mix

–Capital investments targeted at enhanced quality and value

•Pharmaceutical Delivery Systems

–Deliver the potential of Daikyo CZ products

–Increase healthcare-consumable contract manufacturing revenue

–Grow proprietary safety and delivery system businesses

•Financial discipline

–Operating cash flow: Discretionary SG&A, R&D and capital spending that
are supported by revenue growth

–Deliver returns on invested capital (“ROIC”) that regularly exceed weighted
average cost of capital (“WACC”)

–Align incentives with financial performance and value creation

22

Long-Term Growth Opportunity

2 billion combined markets for safety,
prefilled syringes and auto-injectors, with unit
growth of 6%-12%, depending on product
and therapeutic segment

Strategic Planning Goals:

•Projected 2014 sales of $0.6 billion

•Projected 2014 Operating margin: > 20%

$1.5 billion market for components with unit
growth 0% to 8% per year, depending on
product and therapeutic segment

Strategic Planning Goals:

•Projected 2014 sales of $1.0 billion

•Projected 2014 Operating margin: > 20%

Pharmaceutical

Packaging Systems

Primary Container Solutions

Pharmaceutical Delivery

Systems

Administration Systems

Consolidated 2014 Planning Objectives

•2014 Sales: $1.6 billion

•2014 Operating Margin: 19%

23

Summary First Quarter Results$ millions, except per-share data

(1)These are Non-GAAP Financial Measures and exclude the effects of: Restructuring and related pre-tax charges of $1.9
million and $0.6 million in the 2011 and 2010 periods, respectively; and, of $0.2 million of discrete tax items in the 2011
period.Further explanations of those items and were included in the press release announcing first-quarter 2011 results,
which is available through the Company’s website, www.westpharma.com,and in Form 10-Q for the 2011 period.

	Three Months Ended March 31
	2011	2010
Net Sales	$295.4	$274.7
Gross Profit	88.0	82.2
Reported Operating Profit	28.8	28.9
Adjusted Operating Profit (1)	30.7	29.5
Reported Diluted EPS	$0.56	$0.57
Adjusted Diluted EPS(1)	$0.60	$0.58

	Raw Material Cost
Factor Pricing (modestly higher) Unit Volume (slow growth) Mix (continuing shift) cost increases) Raw material costs (higher) Labor (~ inflation)
	Comprise approximately 1/3rd of COGS Materials include: Synthetic elastomers and polymer and film (petroleum based), aluminum, natural rubber 2011 plans based on expected 5% increases vs. YTD actual material price increases that have been notably higher (oil, natural rubber, aluminum ingot). Mitigation: • Cost: Ø Contractual terms for purchases delay pass-through of oil surcharges ØHedging program •Revenue: ØContracted sales price escalators ØMaterial surcharges on other sales

25

26

Pharmaceutical Packaging Systems

Pharmaceutical Delivery Systems

•Well positioned

–Substantial market share

–Proprietary technology

–Diversified customer base

–Global footprint

•Stability with growth potential

–Strength in new product pipeline

–Preferred products for biologics

•The financial strength to invest

–Reliable operating cash flow

–Balance sheet strength

Summary

WEST PHARMACEUTICAL SERVICES OVERVIEW

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

Jefferies2011 Global Healthcare Conference

New York, NY June 6, 2011

© 2011 by West Pharmaceutical Services, Inc., Lionville, PA

All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means,
electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.

Trademarks and registered trademark are the property of West Pharmaceutical Services, Inc., in the United States and other jurisdictions, unless noted otherwise.

Daikyo Crystal Zenith®is a registered trademark of Daikyo Seiko, Ltd.

Crystal Zenith® and FluroTec®technologies are licensed from Daikyo Seiko, Ltd.